Anthropic Moves Into Drug Development With Claude Science

Researchers at the Weizmann Institute of Science have developed an AI tool that reconstructs images from brain scans with notable accuracy by analyzing fMRI data. The system works bidirectionally, predicting both what a person sees from their brain activity and their brain response to visual stimuli. While developers see therapeutic potential for locked-in patients and dream analysis, neuroscientists warn the technology could enable non-consensual extraction of thoughts and mental imagery.

DeepMind has demonstrated a proof of concept for watermarking AI-generated proteins while maintaining their biological function. The technique, called SynthID Bio, embeds identifying markers into synthetic proteins to distinguish them from naturally occurring ones. This addresses a key challenge in synthetic biology: ensuring traceability and authenticity of AI-designed biological molecules without compromising their utility.

AMD is acquiring World Labs, an AI research company co-founded by prominent researcher Dr. Fei-Fei Li, for approximately $8.2 billion in an all-stock deal. World Labs, founded in 2024, developed Marble, a world generation model that creates interactive 3D environments from text prompts. The acquisition positions AMD to expand its AI capabilities and research focus, with Li joining as executive vice president and chief scientist. The deal is expected to close by year-end.

Researchers Li and Lai demonstrated that large language models can predict precise structural edits to make computationally designed molecules synthetically feasible. The approach outperforms traditional optimization methods while preserving the molecular features that matter for drug efficacy. This addresses a persistent bottleneck in computational drug design, where AI-generated candidates often cannot be manufactured.